Nurse Practitioner Program year 2021 Source: CMS Open Payments, 2026 publication

Paula Slack

Nurse Practitioner Ann Arbor, MI Nurse Practitioner

NPI 1174858914 CMS profile 10914821

4260 Plymouth Rd, Ann Arbor, MI 48109

Open in the dashboard

General payments

$401

27 records reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, Paula Slack of Ann Arbor, MI is reported in the CMS Open Payments database as having received $401 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $401 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paula Slack
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Paula Slack were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Paula Slack Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $401 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2021
  1. Mylan Specialty L.P. $130 9 payments
  2. GlaxoSmithKline, LLC. $70 5 payments
  3. AstraZeneca Pharmaceuticals LP $39 3 payments
  4. Pulmonx Corporation $32 2 payments
  5. Insmed, Inc. $27 2 payments
  6. Mallinckrodt Hospital Products Inc. $25 2 payments
  7. Alexion Pharmaceuticals, Inc. $24 1 payment
  8. Philips Electronics North America Corporation $21 1 payment
  9. Penumbra, Inc. $18 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Food and Beverage $401 27 payments
Products named General payments · program year 2021
  1. YUPELRI $130 9 payments
  2. Perforomist $111 8 payments
  3. TRELEGY ELLIPTA $70 5 payments
  4. CHARTIS CATHETER $32 2 payments
  5. ZEPHYR DELIVERY CATHETER $32 2 payments
  6. ZEPHYR ENDOBRONCHIAL VALVE $32 2 payments
  7. PULMONX CHARTIS TABLET CONSOLE $32 2 payments
  8. Arikayce $27 2 payments
  9. ACTHAR $25 2 payments
  10. Ultomiris $24 1 payment
  11. Other $76 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

4,356

Median for Nurse Practitioner: 389

Drug cost

$299,484

Median for Nurse Practitioner: $21,885

Branded share of claims

17%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 73 $82,251
Myrbetriq Mirabegron Brand 63 $42,272
Xarelto Rivaroxaban Brand 19 $25,227
Farxiga Dapagliflozin Propanediol Brand 29 $22,974
Jardiance Empagliflozin Brand 14 $21,250
Spiriva Respimat Tiotropium Bromide Brand 11 $9,364
Spiriva Handihaler Tiotropium Bromide Brand 12 $8,939
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 32 $7,122
Buprenorphine Generic 30 $6,032
Rivastigmine Generic 19 $4,656

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$45,753

Medicare's payments for the services billed

Medicare patients

288

Average age 79

Services billed

833

201 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Depression 40%
Chronic kidney disease 36%
Ischemic heart disease 33%
Osteoporosis 32%
Diabetes 29%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record